{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:56:25Z","timestamp":1785545785978,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Global Services, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20\/2\/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG). Key outcomes included progression-free survival from SMM diagnosis to active MM diagnosis or death (PFS), progression-free survival from SMM diagnosis to progression on first line (1\u2009L) MM treatment or death (PFS2), and overall survival (OS). Of 498 patients, 174 (34.9%) were classified as high risk and 324 (65.1%) as non\u2013high risk. Median follow-up was approximately 65 months. During follow-up, more patients in the high-risk vs non\u2013high-risk group received 1\u2009L MM treatment (76.4% vs 46.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). PFS, PFS2, and OS were significantly shorter in high-risk vs non\u2013high-risk patients (13.2 vs 56.6 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; 49.9 vs 84.9 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; 93.2 vs 131.1 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.012, respectively). The results of this study add to the growing body of evidence that patients with high-risk vs non\u2013high-risk SMM have significantly worse outcomes, including OS.<\/jats:p>","DOI":"10.1038\/s41408-023-00906-7","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T03:29:24Z","timestamp":1695785364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies"],"prefix":"10.1038","volume":"13","author":[{"given":"Viera","family":"Sandecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Popkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Maisnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Jungova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Pavlicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Stejskal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Heindorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmila","family":"Obernauerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evzen","family":"Gregora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ullrychova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Wrobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-9253","authenticated-orcid":false,"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kunovszki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacheeta","family":"Bathija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Wilbertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5283","authenticated-orcid":false,"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"906_CR1","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069\u201375. https:\/\/doi.org\/10.1182\/blood-2014-09-568899.","journal-title":"Blood"},{"key":"906_CR2","unstructured":"UAMS Health. Smoldering myeloma. 2022. https:\/\/uamshealth.com\/condition\/smoldering-myeloma\/."},{"key":"906_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"key":"906_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.100","volume":"6","author":"A Ravindran","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6:e486. https:\/\/doi.org\/10.1038\/bcj.2016.100.","journal-title":"Blood Cancer J"},{"key":"906_CR5","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1056\/NEJMc1310911","volume":"369","author":"SY Kristinsson","year":"2013","unstructured":"Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk smoldering myeloma. N Engl J Med. 2013;369:1762\u20133. https:\/\/doi.org\/10.1056\/NEJMc1310911.","journal-title":"N Engl J Med"},{"key":"906_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood-2021-148617","volume":"138","author":"S Thorsteinsdottir","year":"2021","unstructured":"Thorsteinsdottir S, Gislason G, Aspelund A, R\u00f6gnvaldsson S, Oskarsson J, Petursdottir I, et al. Prevalence of smoldering multiple myeloma: results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study. Blood. 2021;138:151.","journal-title":"Blood."},{"key":"906_CR7","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582\u201390. https:\/\/doi.org\/10.1056\/NEJMoa070389.","journal-title":"N Engl J Med"},{"key":"906_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1182\/blood.2021011670","volume":"140","author":"I Vaxman","year":"2022","unstructured":"Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828\u201338. https:\/\/doi.org\/10.1182\/blood.2021011670.","journal-title":"Blood"},{"key":"906_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/hematology.2021000304","volume":"2021","author":"A Visram","year":"2021","unstructured":"Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematology Am Soc Hematol Educ Program. 2021;2021:673\u201381. https:\/\/doi.org\/10.1182\/hematology.2021000304.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"906_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59. https:\/\/doi.org\/10.1038\/s41408-018-0077-4.","journal-title":"Blood Cancer J"},{"key":"906_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102. https:\/\/doi.org\/10.1038\/s41408-020-00366-3.","journal-title":"Blood Cancer J"},{"key":"906_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.16572","volume":"190","author":"R H\u00e1jek","year":"2020","unstructured":"H\u00e1jek R, Sandecka V, \u0160pi\u010dka I, Raab M, Goldschmidt H, Beck S, et al. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. Br J Haematol. 2020;190:189\u201397. https:\/\/doi.org\/10.1111\/bjh.16572.","journal-title":"Br J Haematol"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1097\/HS9.0000000000000528","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528. https:\/\/doi.org\/10.1097\/HS9.0000000000000528.","journal-title":"Hemasphere"},{"key":"906_CR14","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 5.2022. Multiple Myeloma. 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"906_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14735\/amko20172S43","volume":"30","author":"L Brozova","year":"2017","unstructured":"Brozova L, Schwarz D, Snabl I, Kalina J, Pavlickova B, Komenda M, et al. Czech Registry of Monoclonal Gammopathies - technical solution, data collection and visualisation. Klin Onkol. 2017;30:43\u201350. https:\/\/doi.org\/10.14735\/amko20172S43.","journal-title":"Klin Onkol"},{"key":"906_CR16","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/j.clml.2018.04.003","volume":"18","author":"R H\u00e1jek","year":"2018","unstructured":"H\u00e1jek R, Jarkovsky J, Maisnar V, Pour L, \u0160pi\u010dka I, Mina\u0159\u00edk J, et al. Real-world outcomes of multiple myeloma: retrospective analysis of the Czech Registry of Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk. 2018;18:e219\u201340. https:\/\/doi.org\/10.1016\/j.clml.2018.04.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"906_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14735\/amko20172S35","volume":"30","author":"D Maluskova","year":"2017","unstructured":"Maluskova D, Svobodov\u00e1 I, Kucerova M, Brozova L, Muzik J, Jarkovsk\u00fd J, et al. Epidemiology of multiple myeloma in the Czech Republic. Klin Onkol. 2017;30:35\u201342. https:\/\/doi.org\/10.14735\/amko20172S35.","journal-title":"Klin Onkol"},{"key":"906_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126\u201337. https:\/\/doi.org\/10.1200\/JCO.19.01740.","journal-title":"J Clin Oncol"},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3390\/curroncol28030188","volume":"28","author":"C Tessier","year":"2021","unstructured":"Tessier C, Allard T, Boudreault JS, Kaedbey R, Ethier V, Fortin F, et al. Testing Mayo Clinic\u2019s New 20\/20\/20 risk model in another cohort of smoldering myeloma patients: a retrospective study. Curr Oncol. 2021;28:2029\u201339. https:\/\/doi.org\/10.3390\/curroncol28030188.","journal-title":"Curr Oncol"},{"key":"906_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(16)30124-3.","journal-title":"Lancet Oncol"},{"key":"906_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","volume":"174","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Hern\u00e1ndez MT, Salvador C, Rubia J, de Arriba F, L\u00f3pez-Corral L, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study. Eur J Cancer. 2022;174:243\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.030.","journal-title":"Eur J Cancer"},{"key":"906_CR22","doi-asserted-by":"publisher","first-page":"TPS8075","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8075","volume":"40","author":"M Dimopoulos","year":"2022","unstructured":"Dimopoulos M, Voorhees P, Goldschmidt H, Baker R, Shi Y, Rousseau E, et al. Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): randomized, open-label, phase 3 AQUILA study. J Clin Oncol. 2022;40:TPS8075.","journal-title":"J Clin Oncol"},{"key":"906_CR23","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/S2152-2650(21)02264-3","volume":"21","author":"I Ghobrial","year":"2021","unstructured":"Ghobrial I, Rodr\u00edguez-Otero P, Koh Y, Mart\u00ednez-L\u00f3pez J, Parmar G, Prince M, et al. ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma: safety run-in preliminary results. Clin Lymphoma Myeloma Leuk. 2021;21:S109\u201310.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"906_CR24","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00432-019-02998-w","volume":"145","author":"MA Baertsch","year":"2019","unstructured":"Baertsch MA, Lutz R, Raab MS, Weinhold N, Goldschmidt H. Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow. J Cancer Res Clin Oncol. 2019;145:2445\u201355. https:\/\/doi.org\/10.1007\/s00432-019-02998-w.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00906-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00906-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00906-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:02:38Z","timestamp":1700319758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00906-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00906-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TP, M Stork, AJ, LS, LP, AH, JO, EG, M Sykora, JU, and MW declare no competing interests. VS: consultancy roles: Amgen, Janssen, Sanofi, and Taketa; financial support (for attending meetings and\/or travel): Amgen, Celgene, Janssen, Sanofi, and Takeda; and honoraria: Amgen, Janssen, Sanofi, and Takeda. P Kessler: speaker: Takeda. VM: consultancy roles: Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Sanofi, Takeda, and The Binding Site; advisory board participation: Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Sanofi, and Takeda; financial support (for attending meetings and\/or travel): Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; honoraria: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi, Takeda, and The Binding Site. JM: consultancy roles: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi, and Takeda; advisory board participation: Oncopeptides; financial support (for attending meetings and\/or travel): Bristol-Myers Squibb, Janssen, and Takeda; and honoraria: Bristol-Myers Squibb, Celgene, Janssen, Sanofi, and Takeda. PP: grants: Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Jansen, Sanofi, and Takeda. TJ: grants: Amgen and Sanofi; and honoraria: Bristol-Myers Squibb, GlaxoSmithKline, Janssen, and Takeda. P Kunovszki, SB, BG, SW, QC, and AL: employees: Janssen. IS: consultancy roles: Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, PharmaMar, Sanofi, and Takeda; advisory boards participation: Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, PharmaMar, Sanofi, and Takeda; financial support (for attending meetings and\/or travel): Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; honoraria: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi, and Takeda; and other financial\/nonfinancial interests: Amgen, Bristol-Myers Squibb, Celgene, and Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}